NMOSD

Newly approved treatments in neuromyelitis optica spectrum disorder have shown efficacy in recent years, yet unaddressed concerns voiced by clinicians and patients living with the disease remain.

The approval is supported by phase 3 data which showed ravulizumab-cwvz met its primary end point of time to first on-trial relapse, with no relapses observed in 58 patients with NMOSD over a median treatment duration of 73 weeks.

A recent analysis revealed a significant association between neuromyelitis optica spectrum disorder and connective tissue disease in patients diagnosed or suspected with Sjogren syndrome.

A recent study highlighted the potential of susceptibility-weighted image features as imaging biomarkers to differentiate patients with multiple sclerosis from those with neuromyelitis optica spectrum disorder.

Patients with aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorder exhibited higher urine pH compared to those with multiple sclerosis and healthy controls.

Patients with non-P42 MOG-IgG in MOGAD had over three times higher risk of relapsing course than those with P42 MOG-IgG.

As part of our monthly clinician spotlight, NeurologyLive® highlighted rare disease medicine expert Paula Barreras, MD, a physician neurologist and neuroimmunologist at Cedars Sinai Medical Center.

In recent news, Health Canada approved inebilizumab for adult patients with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive, using results from the N-MOmentum trial as the basis for the approval.

A recent analysis revealed a reduction in regulatory lymphocyte subsets in patients with NMOSD before tocilizumab therapy, with subsequent restoration to normal levels after 1 year treatment.

In a recent study, investigators observed a substantial up-regulation of long noncoding RNAs among patients with neuromyelitis optica spectrum disorder in comparison with heathy individuals.

Investigators identified practical guidelines for NMOSD management, emphasizing patient communication and targeted therapies, while providing recommendations for personalized approaches.

A recent analysis revealed patients with neuromyelitis optica spectrum disorder exhibited significantly lower vitamin D levels, suggesting a potential association with impaired immune tolerance in the disorder.

A recent study identified specific risk factors influencing readmission odds in patients with neuromyelitis optica spectrum disorder, contributing valuable insights for predictive algorithms and improved patient outcomes.

Patients with neuromyelitis optica spectrum disorder experienced poor sleep quality, indicating a significant contribution to the overall disease burden.

A recent study revealed that susceptibility-based imaging can effectively differentiate pediatric-onset multiple sclerosis from pediatric myelin oligodendrocyte glycoprotein antibody-associated disease.

A recent meta-analysis revealed significant differences in characteristic between patients with NMOSD and MS, highlighting the need for enhanced tools to differentiate between these diseases for early and accurate diagnosis.

A recent subgroup analysis of the N-MOmentum study revealed that inebilizumab had equal efficacy in reducing attacks among Asian and nonAsian patients with NMOSD, demonstrating its continued superiority over placebo.

Across 31 studies of patients with NMOSD, more than half of the patients included reported having sleep disturbances associated with their condition.

The physician neurologist and neuroimmunologist at Cedars Sinai Medical Center discussed RNDS 2023, an educational event for Spanish-speaking patients with rare neuroimmune disorders.

Insurance coverage or cost was considered a barrier to prescribing novel NMOSD treatments in 42% of respondents, with the highest rate seen in eculizumab.

A recent meta-analysis on tocilizumab in neuromyelitis optica spectrum disorder (NMOSD) emphasized its effectiveness in reducing relapse rates and improving patient function, with patient-specific factors influencing outcomes.

Data from a US database suggest that patients who switched to eculizumab (Soliris; Alexion) significantly reduced their hospitalization, days hospitalized, and documented comorbidities.

The clinical research director of the UCSF Multiple Sclerosis Center talked about a clinical trial highlighting the therapeutic benefits of longterm treatment with inebilizumab in patients with NMOSD. [WATCH TIME: 4 minutes]

A new analysis of the SAkuraMoon study showed that annual relapse rate remained consistently low in satralizumab-treated patients, with high proportions of patients remaining free from relapse, severe relapse, and worsening in disability.

A recent analysis of the PREVENT and CHAMPION-NMOSD found no significant differences in safety outcomes for patients with AQP4+ NMOSD who were treated with rituximab prior to starting C5 complement inhibitors in specific timeframes.